Recently, the Th1/Th2 paradigm has been expanded, following the discovery of a third subset of the effector Th cells, called Th17 cells[@b1][@b2][@b3] and characterized by the production of IL-17A, IL-17F, and IL-22 as the signature cytokines. In the presence of TGF-β alone, naive T cells express Foxp3 that induces the regulatory T cells[@b4]. A relevant finding is that IL-6 is a potent inhibitor of the TGF-β-driven induction of Foxp3^+^ regulatory T cells[@b5]. IL-6 not only inhibits the generation of these cells, but also together with TGF-β, guides the naive CD4^+^ T cells to produce IL-17. Th17 cells express a unique transcription factor, RORγt[@b6], which induces the transcription of the *Il-17* gene in naive helper T cells to promote the development of IL-17-producing cells in the presence of TGF-β and IL-6[@b7]. RORγt activation also induces the expression of IL-23R, indicating that IL-23 acts on T cells that are already committed to the Th17 lineage[@b8]. It is well known that the Th17 cells play a key part in the pathogenesis of the autoimmune and inflammatory diseases as well as the tumors. Thus, it is of great significance to reveal the mechanisms that regulate the Th17 cell differentiation.

Notch signaling has been proven to decide the fates of immune cells. In mammals, there are four Notch receptors, including Notch-1, Notch-2, Notch-3 and Notch-4, and five Notch ligands, including Jagged-1, Jagged-2, delta-1 (Dll1), delta-3 (Dll3) and delta-4 (Dll4). Jagged-1 is taken as the example. While Jagged-1 interacts with the Notch-1 or Notch-2, successive cleavages are triggered in the transmembrane region of Notch receptors by the disintegrin and metalloproteinase. The endocytosis of the transmembrane fragment of the Notch contributes to the further cleavage by γ-secretase, leading to the release of the Notch intracellular domain and the final activation of the Notch signaling pathway.

Radtke *et al*. found that the deletion of Notch-1 resulted in the marked decrease in the size of thymus that lacked T cells and contained the excess of B cells[@b9][@b10]. Notch-1 inactivation causes a complete block in T lineage development, indicating that the other Notch family members cannot compensate for the loss of Notch-1 *in vivo*[@b10]. Notch signaling not only regulates the T/B cell lineage commitment, but also the differentiation and function of the peripheral T cells[@b11][@b12]. Different Notch ligands play various roles in the differentiation of the naive CD4^+^ T cells. The antigenic stimulation of the naive CD4^+^ T cells in the context of antigen-presenting cells engineered to express Dll1 leads to the secretion of Th1 cytokines, such as IFN-γ[@b13], whereas the Jagged-1 promotes the Th2 cytokine production, such as IL-4[@b14]. Mukherjee *et al*. found that the dendritic cells (DCs) were activated by TLR-specific signals, and Dll4 up-regulated the RORγt expression in T cells; both *rorγt* and *il17* gene promoters were the direct transcriptional notch targets that further enhance the differentiation of Th17 cell populations, while anti-Dll4Ab significantly inhibited the differentiation[@b15]. Ito *et al*. showed that the TLR9-deficient mice challenged with a mycobacterium antigen displayed an altered Th17 cytokine profile, the decreased accumulation of granuloma-associated myeloid DCs, and profoundly reduced Dll4 expression, suggesting that the Dll4 plays an important role in promoting the Th17 activity during mycobacterium challenge[@b16]. Notch-3 antibody could down-regulate the expression of IL-17 in experimental autoimmune encephalomyelitis. These data suggest that the Dll-Notch signaling may be involved in the differentiation of Th17 cells[@b17]. Our previous study showed that the Jagged-1--Hes-1 signaling could reduce the production of IL-17 in CD4^+^ T cells, which was reversed by Hes-1-targeting siRNA[@b18]. However, it is still unclear how genes relevant to autoimmunity or inflammation are altered in the Jagged-1-treated cells. Therefore, in the current study, qPCR array was used for the first time to explore the genes that may play an important part in the Jagged-1-mediated Th17 cell differentiation from different angles.

Results
=======

Jagged-1--Notch signaling inhibits the differentiation of the CD4^+^ T cells into Th17 cells
--------------------------------------------------------------------------------------------

Flow cytometry was performed to analyze the phenotypes of CD4^+^ T cells treated with Jagged-1. As shown in [Fig. 1](#f1){ref-type="fig"}, compared with the anti-CD3/CD28 group, the group, treated simultaneously by IL-6 and TGF-β, showed the increased percentage of CD4^+^IL-17^+^ T cells. This augment can be abolished by Jagged-1. However, the percentage of IFN-γ^+^IL-17^+^ T cells was unchanged in each group. The results indicate that the activation of the Jagged-1 signaling can inhibit the polarization of Th17 cells without the enhancement of Th1-like cytokine.

Jagged-1--Notch signaling elicits the differential expression in genes in the CD4^+^ T cells
--------------------------------------------------------------------------------------------

Among the assessed 84 genes, 21 genes were markedly changed with the changes greater than 2.0 fold, including 3 upregulated genes, ie. chemokine (C-X-C motif) ligand 12 (*cxcl12*), chemokine (C-X-C motif) ligand 2 (*cxcl2*) and matrix metallopeptidase 3 (*mmp3*); and 18 downregulated genes, ie. c-type lectin domain family 7 member a (*clec7a*), colony stimulating factor 3 (*csf3*), interleukin 12b (*il12b*), interleukin12 receptor beta1 (*il12rb1*), interleukin 12 receptor beta 2 (*il12rb2*), interleukin 15 (*il15*), interleukin 17a (*il17a*), interleukin 17d (*il17d*), interleukin 17f (*il17f*), interleukin 17 receptor C (*il17rc*), interleukin 17 receptor D (*il17rd*), interleukin 17 receptor E (*il17re*), interleukin 23 alpha (*il23a*), myeloid differentiation primary response gene 88 (*myd88*), suppressor of cytokine signaling 1 (*socs1*), signal transducer and activator of transcription 4 (*stat4*), signal transducer and activator of transcription 5a (*stat5a*), spleen tyrosine kinase (*sykb*) and T-box 21 (*tbx21*). Especially, there was 3-fold downregulation in the expression of IL17a, but over 35-fold in that of IL17f. The differential gene expressions in the CD4^+^ T cells treated with Jagged-1 were showed in HeatMap and ScatterPlot, respectively ([Fig. 2A--B](#f2){ref-type="fig"}). Their names and the significant differences in the gene expression profiles in CD4^+^ T cells between Jagged-1 and control groups were presented in [Fig. 2C--D](#f2){ref-type="fig"}. The data indicate that the activation of Jagged-1 signaling results in the downregulation of some genes (*clec7a, il12b*, *il12rb2* and *il15*) to promote the proliferation of T cells or NK cells; and some genes (*tbx21, stat4, il12b, il12rb1, il12rb2, il17a, il17f, il17rc* and *il23a*) to influence the polarization and stability of Th1 cells or Th17 cells, and the other genes (*il17rd* and *il17re*) to activate the MAPK signaling pathway. Additionally, we also noted that *cxcl12* (with chemotactic influence on T cells and monocytes), *cxcl2* (with chemotactic impact on neutrophil) and *mmp3* (with hydrolysis of the collagen) were upregulated, the significance of which is unclear.

The reduction in the expressions of *il-17a*, *il-17f*, *il-12rb1* and *il-23a* by Jagged-1--Notch signaling
------------------------------------------------------------------------------------------------------------

The Jagged-1--Notch-1 signaling induced changes in *il-17a*, *il-17f*, *il-12rb1* and *il-23a* were further confirmed by RT-PCR ([Fig. 3A--D](#f3){ref-type="fig"}) and qPCR ([Fig. 3E--H](#f3){ref-type="fig"}). As shown in [Fig. 3](#f3){ref-type="fig"}, compared with the group treated with IL-6/TGF-β/IL-23a in the presence of anti-CD3/CD28, the activation of Jagged-1--Notch signaling indeed led to the decrease of *il-17a*, *il-17f*, *il-12rb1* and *il-23a* levels in the CD4^+^ T cells, consistent with the alterations observed by qPCR array. However, there was no difference between IL-17A and IL-17F, different from the qPCR array data. These results show that the Jagged-1 can inhibit the Th17 cell differentiation, maturation and stability.

Jagged-1--Notch-1 signaling inhibits the specific cytokine production in Th17 cells via RORγt
---------------------------------------------------------------------------------------------

IL-17A and IL-17F were considered as functional executants of Th17 cells. qPCR and Western Blot were first used to evaluate the relationship among RORγt, IL-17A and IL-17F. Compared with the anti-CD3/CD28 group, both IL-6 and TGF-β could obviously increase the expressions of RORγt, IL-17A and IL-17F mRNAs, but Jagged-1 could decrease their expressions in the CD4^+^ T cells induced by simultaneous IL-6 and TGF-β treatment ([Fig. 4A--C](#f4){ref-type="fig"}). Following the alterations in RORγt, IL-17A and IL-17F mRNAs, RORγt, IL-17A and IL-17F protein levels were also decreased. Both IL-6 and TGF-β upregulated the expressions of RORγt, IL-17A and IL-17F, whereas this augment could be abrogated by Jagged-1 ([Fig. 4D--F](#f4){ref-type="fig"}). Furthermore, the secretion of IL-17A and IL-17F in the treated cells was tested by ELISA. Compared with the anti-CD3/CD28 group, simultaneous IL-6 and TGF-β treatment boosted the cells to secrete IL-17A and IL-17F, which could be reversed by Jagged-1 ([Fig. 4G--H](#f4){ref-type="fig"}). These findings further support that the Jagged-1--Notch-1 signaling inhibits the production of IL-17A and IL-17F in the CD4^+^ T cells via RORγt. The qPCR array data showed that the level of IL-17F in the treated cells was lower than that of IL-17A. It seems that IL-17F might play a more important role in Th17 cell polarization, but other results demonstrate that there is no significant difference between the both.

Jagged-1--Notch-1 signaling inhibits the *in situ* expressions of RORγt, IL-17A and IL-17F induced by simultaneous IL-6 and TGF-β treatment
-------------------------------------------------------------------------------------------------------------------------------------------

As shown in [Fig. 5](#f5){ref-type="fig"}--[6](#f6){ref-type="fig"}, CD4^+^ T cells were treated with IL-6, TGF-β and Jagged-1 for 72 h to find out the effects of Jagged-1--Notch-1 signaling on the *in situ* expressions of RORγt, IL-17A and IL-17F in the CD4^+^ T cells. Compared with the anti-CD3/CD28 group, the group, treated simultaneously by IL-6 and TGF-β, showed the enhanced *in situ* expressions of RORγt, IL-17A, and IL-17F. The *in situ* expressions of RORγt, IL-17A and IL-17F in the CD4^+^ T cells induced by simultaneous IL-6 and TGF-β treatment were obviously decreased after the treatment by Jagged-1. Moreover, the changes in IL-17A and IL-17F levels were consistent with the RORγt expression. The data further support that the activation of Jagged-1--Notch-1 signaling pathway may inhibit the differentiation of CD4^+^ T cells towards Th17 cells induced by simultaneous IL-6 and TGF-β treatment via the reduction of RORγt/IL-17A/IL-17F/IL-23a/IL-12rb1.

Discussion
==========

Naive CD4^+^ T cells express Notch-1 and Notch-2 receptor mRNAs, while they do not express Notch-3 and Notch-4 mRNAs[@b14]. T cells express Notch ligands Jagged-1[@b24], Jagged-2[@b25], and Delta-1[@b26]. DCs treated with lipopolysacride can express Notch ligands Jagged-1 and Jagged-2 as well as Delta-4[@b14][@b24][@b25]. Jagged-1 was originally isolated as a mammalian ligand that activates the Notch-1 signaling. The activated domain has been mapped to a N-terminal extracellular region of Jagged-1, as a specific peptide from the Delta/Serrate/Lag2 (DSL)-domain of Jagged-1 that can mediate the activation of Notch signaling[@b27].

There are debates about the suppression of T cell activation or the enhancement of T cell function by Notch signaling in murine and human systems[@b28]. Notch ligands have been shown to differently influence the T cell differentiation[@b29][@b30][@b31]. Yasutomo *et al*. first demonstrated that Dll1 could promote the skewing of naive CD4^+^ T cells toward Th1[@b29]. Subsequently, Amsen *et al*. found that Jagged-1 could induce naïve CD4^+^ T cells to differentiate into Th2 lineage by increasing the expression of IL-4 in naïve CD4^+^ T cells[@b14]. Other investigators showed that Jagged-1 directly activated a Jagged-1--Notch signaling pathway, inducing naïve peripheral T cells to differentiate into regulatory T cells[@b30][@b31]. Furthermore, Ito *et al*. found that Dll4 would improve the secretion of Th17 cytokines, such as IL-17A and IL-17F *in vitro* and *in vivo*. Dll4 influences the generation of IL-17-producing T cells in the presence of both IL-6 and TGF-β[@b16]. Our previous data indicate that the Jagged-1-Hes-1 signaling can suppress the skewing of CD4^+^ T cells toward Th17 cells by means of siRNA to knockdown *hes-1* gene, but the genes that function in the Th17 cell skewing remain poorly understood[@b18]. In this study, we observed the alterations in 84 genes possibly related to the differentiation of Th17 cells for the first time to find out the genes that play a prominent part in the differentiation induced by Jagged-1. The novel findings demonstrate that *cxcl12, cxcl2 and mmp3* gene expressions are increased, but *clec7a, csf3, il12b, il12rb1, il12rb2, il15, il17a, il17d, il17f, il17rc, il17rd, il17re, il23a, myd88, socs1, stat4, stat5a, sykb and tbx21* expressions are decreased. Some of the downregulated genes, such as *il12b, il12rb1, il12rb2, stat4 and tbx21*, might be related to Th1 cell polarization, but others, mainly including *il17a, il17d, il17f, il17rc, il17rd, il17re and il23a*, might be related to Th17 cell skewing. Furthermore, *il17a*, *il17f*, *il12rb1* and *il23a* were selected for further confirming their relationship to Jagged-1 signaling. They were indeed reduced in the treated cells, which is consistent with the attenuation of CD4^+^IL17^+^ T cells. The downregulation of IL17a, IL17f, IL17rc, IL17rd and IL17re contributes to the inhibition of Th17 cell skewing by Jagged-1. Are they correlated to RORγt change? The reductions in both IL17A and IL17F are attributed to the decreased expression of RORγt by Jagged-1, and that Jagged-1 signaling is responsible for the reduction in IL12rb1, which may avail the inhibition of naïve CD4^+^ T cell skewing toward Th1. In addition, the reduction in IL23a by Jagged-1 may preclude the maturation of Th17, contributing to the decreased number of CD4^+^IL17^+^ T cells by Jagged-1 signaling, too. Undoubtedly, these findings provide a novel insight into the mechanisms of Th17 cell differentiation. Of course, it merits to exploring further the roles that Cxcl12, Cxcl2 and Mmp3 play in the Jagged-1-inhibited Th17 cell skewing.

IL-23 is a member of IL-12 family of heterodimeric cytokines. It is composed of two subunits: IL-12p40, which is common to IL-12, and IL-23-specific p19 subunit[@b32]. The reported relationships of IL-12 and Th1 cells with autoimmunity can be explained by the requirement for IL-23[@b33]. Many of the proinflammatory functions of IL-23 seem to be related to Th17 cell subset[@b34]. The stimulation of IL-23 maintains the IL-17 production by Th17 cells[@b35], that enhances the Th17 cell differentiation[@b32], or promotes the survival of Th17 cells[@b36]. In the presence of proinflammatory cytokines particularly, TGF-β and IL-6 can trigger the Th17 differentiation through Th17-specific transcription factor RORγt, which leads to the production of IL-17A and IL-17F[@b3][@b5][@b37]. IL-23R is up-regulated on the membrane of the naïve CD4^+^ T cells after activation in the presence of IL-6[@b6]. IL-23R is induced in the developing Th17 cells, and IL-12Rb2 is produced in the developing Th1 cells to pair with the constitutively expressed IL-12Rb1 chain to combine with IL-23 and IL-12, respectively. IL-12Rb1 chain binds a common subunit of IL-23 and IL-12 heterodimers (IL-12p40 or IL-12b) to pair with IL-23p19 (IL-23a) or IL-12p35 (IL-12a), respectively[@b32][@b38][@b39]. In our study, the expressions of *Il17a, Il17f, Il12rb1 and Il23a* were also significantly inhibited by Jagged-1, which was directly related to the observed Th17 phenotype, suggesting that the IL-23 signaling pathway plays a role in the development of Th17 cells. Some reports suggest that the activation of the IL-23 or IL-12 receptor induces late events in the downstream of early Th17 or Th1 lineage commitment[@b1][@b37]. Whereas the IL-12 receptor potently activates Stat4 in Th1 cells, the IL-23 receptor predominantly activates Stat3, but also recruits some Stat4[@b32][@b40][@b41]. Stat3 is required for programming TGF-β1 and IL-6, and the IL-23-stimulated IL-17-secreting phenotype. Moreover, the retroviral transduction of the constitutively active Stat3 into the differentiating T cells enhances IL-17 production, suggesting that the Stat3 may directly regulate the forming of Th17 cells[@b40]. Moreover, the IFN-γ- and IL-17-producing T cells were typically found in association with the IFN-γ-producing T cells in the context of both autoimmune inflammation and infection. These data suggest that there might be a parallel between Th1 and Th17 developmental programs. Our results show that the Jagged-1 does not influence the percentage of IFN-γ-producing CD4^+^ T cells, but significantly decreases the number of IL-17-producing CD4^+^ T cells. The critical cytokines and their receptors to promote Th1 cell skewing, including IL12b, IL12rb1 and IL12rb2, are reduced, and the crucial transcriptional factors to facilitate Th1 cell skewing, including Stat4 and T-box 21 are also attenuated, further supporting our findings.

Although several up to date reports implicate the impact of Notch signaling on the Th17 differentiation, there still exist the opposite effects. Elyaman *et al.* reported that Jagged-1 could protect from the Experimental Autoimmune Encephalomyelitis (EAE), but Dll1 exacerbated its development. On the contrary, the administration of anti-Jagged-1 Ab exacerbated the EAE, while anti-Dll1 Ab reduced its severity. These data suggest that Jagged-1 may inhibit Th17 cell deviation or function[@b42]. In our study, Jagged-1 could reduce the number of CD4^+^IL-17^+^ T cells with the reduction of IL-17A and IL-17F, and did not influence the expression of IFN-γ, indicating that it may suppress the skewing of CD4^+^ T cells toward Th17 nor Th1 cells. Keerthivasan *et al*. obtained the opposite evidence that if Notch signaling was blocked; the production of Th17-associated cytokines was diminished, suggesting that the Notch signaling is required for the Th17 differentiation[@b43]. Of note, Bailis\' team found that Notch did not direct the Th cell differentiation, but instead concurrently regulated the Th1, Th2, and Th17 cell genetic programs mainly by the addition of a gamma secretase inhibitor[@b44]. Through comparison and analysis for the associated reports, we consider that this contradiction or difference might be the result from the differentially polarizing conditions, dissimilarly inducing protocols, different host cells (or models) and evaluating standards.

Taken together, 84 genes relevant to the autoimmunity and inflammation were screened in this study for the first time to explore the potential roles of these genes in the Jagged-1-inhibited Th17 cell differentiation. The novel findings indicate that the activation of Jagged-1 signaling leads to the downregulation of *clec7a, il12b, il12rb1, il12rb2, csf3, il15, il17a, il17f, il17rc, il17rd, il17re, il23a, myd88, socs1, stat4, stat5a, sykb and tbx21*, and the upregulation of *cxcl12*, *cxcl2* and *mmp3* under Th17 cell polarization, and that the Jagged-1 signaling suppresses the simultaneous IL-6 and TGF-β treatment-induced Th17 cell differentiation via the reduction of RORγt/IL-17A/IL-17F/IL-23a/IL-12rb1. The results provide a new insight into Th17 cell differentiation and a potential strategy to inhibit its deviation. Additionally, our results also suggest that the correlation between the screened Il12rb1/Clec7a/Socs1 and RORγt deserves to be further explored in the Jagged-1-inhibited Th17 polarization.

Methods
=======

Mice
----

BALB/c mice were purchased from the Guangzhou Medical Animal Center (Guangzhou, China). Eight week-old animals were used. All animals were bred and maintained under the specific pathogen-free condition. All animal handling and experiment procedures were approved by the Animal Care and Use Committee of Guangzhou Medical Animal Center. All experiments below were performed in accordance with relevant guidelines and regulations.

Immunomagnetic bead isolation
-----------------------------

Peripheral lymph nodes in mice were triturated mechanically and filtered by using the 200 meshes of stainless wire net for the isolation of lymphocytes. Then, the cells were harvested, washed twice with PBS, and re-suspended in Roswell Park Memorial Institute 1640 complete culture medium containing 10% (v/v) fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA) at the concentration of 1 × 10^6^ cells/ml.

CD4^+^ T cells were segregated from the above separated lymphocytes using the mouse naïve CD4^+^ T cell isolation kit (EasySep Negative Selection Kit, StemCell, Vancouver, BC, CA). The lymphocytes were suspended at a concentration of 1 × 10^8^ cells/ml with medium plus 5% normal rat serum in a polystyrene tube. According to the manufacturer\'s instructions, CD4^+^ T Cell Enrichment Cocktail, Biotin Selection Cocktail and Magnetic Nano particles were added into the tube, respectively. The CD4^+^ T cells were enriched in suspension and the unwanted cells were discarded through magnetic labeling. Then, the purity of the separated CD4^+^ T cell population was tested under a flow cytometer, reaching 98%. The collected CD4^+^ T cells were cultured at 37°C in 5% CO~2~ in the complete medium.

Flow cytometry
--------------

The cells were treated with or without 1 μg/ml Jagged-1 (R&D Systems, Minneapolis, MN, USA) for 72 h in the presence of anti-CD3/CD28 beads at a bead-to-cell ratio of 1:1 (Invitrogen, Carlsbad, CA, USA), 20 ng/ml IL-6, 10 ng/ml TGF-β, 20 ng/ml IL-23 (PeproTech, Rocky Hill, NJ, USA), 10 μg/ml anti-IFN-γ and 10 μg/ml anti-IL-4 (eBioscience, San Diego, CA, USA). The additional cells were treated with the equal volume of phosphate buffered saline (PBS) as a control. Six hours before the end of the treatment, the cells were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA) plus 1 μg/ml of ionomycin (Alexis, Lausen, Switzerland) for the below experiments. Meanwhile, 10 μg/ml of GolgiStop (Becton Dickinson, Franklin Lakes, NJ, USA) was added to the cells. The cells were washed with PBS and stained with FITC-conjugated anti-mouse CD4 (0.125 μg per million cells) at 37°C for 20 min. The cells were washed, fixed, permeabilized with Fixation/Permeabilization Buffer and intracellular-stained with PE-conjugated anti-mouse IL-17 (0.05 μg per million cells) and FITC-conjugated anti-mouse IFN-γ (0.25 μg per million cells) (eBioscience, San Diego, CA, USA) for 30 min at 4°C, and analyzed with a flow cytometer (FACSCalibur, Becton Dickinson, Mountain View, CA, USA).

Quantitative PCR array
----------------------

The isolated CD4^+^ T cells were treated with or without 1 μg/ml Jagged-1 for 72 h. Total RNA was extracted using the Trizol RNA Extraction Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. RNA samples were tested for the concentration and purity by Nanodrop 2000 (ThermoFisher Scientific). One microgram of the total RNA was reverse-transcribed to obtain cDNA with a RT^2^ First Strand Kit (QIAGEN GmbH, Hildden, Germany), and applied to PCR array plates. Then, the 84 genes examined using RT^2^ Profiler PCR Array Mouse Th17 for Autoimmunity and Inflammation (PAMM-073A, Qiagen, Germany) are listed in [Table 1](#t1){ref-type="table"} beside 12 genes as genomic DNA contamination control, reverse transcription control and internal control, respectively. 2700 μl of qPCR mixture contained 102 μl of cDNA, 1350 μl of 2 × RT^2^ SYBR Green Mastermix, and 1248 μl of RNase free water. qPCR mixture was added to the array at 25 μl/well. The qPCR reaction conditions were as follows: 95°C for 10 min, 95°C for 15 s, 55°C for 40 s, 72°C for 30 s, and 40 cycles in total. The qPCR was performed on a Bio-Rad/MJ Research Chromo4 (BIO-RAD, Berkeley, CA, USA), and each sample with and without Jagged-1 treatment was repeatedly tested using the array for average of CT values. The 2^−ΔΔCT^ method was performed for the relative quantification of the mRNA expression using the web-based software for the cataloged and custom arrays (<http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php>) (Qiagen, Germany). The gene expressions of the Jagged-1-treated group with changes greater than 2.0 fold were obtained, compared with the control group.

RT-PCR and real-time quantitative PCR
-------------------------------------

To further confirm the changes of the related genes in the CD4^+^ T cells treated with Jagged-1, the cells were treated with or without 1 μg/ml Jagged-1 in the presence of anti-CD3/CD28, IL-6, TGF-β and IL-23 for 72 h, and the total RNA was extracted using a Trizol RNA Extraction Reagent (Invitrogen, Carlsbad, CA, USA). One microgram of the total RNA was used in each reaction primed with oligo-dT to obtain cDNA. Then, 1 μl of the synthesized cDNA was used as a template for RT-PCR or real-time quantitative PCR. The primers were as follows: *Il-17a*[@b19] sense 5′-TCCCTCTGTGATCTGGGAAG-3′, *Il-17a* antisense 5′-CTC GAC CCT GAA AGT GAA GG-3′; *Il-17f*[@b6] sense 5′-GAG GAT AAC ACT GTG AGA GTT GAC-3′, *Il-17f* antisense 5′-GAG TTC ATG GTG CTG TCT TCC-3′; *Il-23a*[@b20] sense 5′-TGG CAT CGA GAA ACT GTG AGA-3′, *Il-23a* antisense 5′-TCA GTT CGT ATT GGT AGT CCT GTT A-3′; *Il-12rb1*[@b21] sense 5′-CGG GGG TCC TGA CGC AAT ACG-3′, *Il-12rb1* antisense 5′-CTC CGG GCA TCT CGA CCA CCA G-3′; *Rorγt*[@b22] sense 5′-GCT GTC AAA GTG ATC TGG AG-3′, *Rorγt* antisense 5′-GGT GGA ACT TAT GGG AAA TC-3′; *β-actin*[@b23] sense 5′-AAC AGT CCG CCT AGA AGC AC-3′, *β-actin* antisense 5′-CGT TGA CAT CCG TAA AGA CC-3′. The amplified products were separated by electrophoresis on a 1.5% agarose gel, analyzed using the FluorChem 8000 system(Alpha Innotech, Santa Clara, CA, USA) and the Jagged-1/*β-*actin ratio was calculated.

Real-time qPCR was performed on an ABI7300 sequence detection system (Applied Biosystems). The real-time qPCR reaction was amplified with the following procedure: 95°C for 10 min, and 35 repeats at 95°C for 30 s, 60°C for 30 s and 72°C for 30 s. The 2^−ΔΔCt^ method was performed for the relative quantification of mRNA expression.

Western Blot
------------

The cells were treated as described in the "Flow cytometry" section. Six hours before the end of the treatment, the cells were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA) plus 1 μg/ml of ionomycin (Alexis, Lausen, Switzerland) for the below experiments. Meanwhile, 10 μg/ml of GolgiStop (Becton Dickinson, Franklin Lakes, NJ, USA) was added to the cells. The treated cells were lysed with radio-immunoprecipitation assay (RIPA) lysis buffer (BioColors, Shanghai, China) containing phenylmethanesulfonyl fluoride. The proteins were analyzed on SDS-PAGE gels and electrophoretically transferred onto the nitrocullose membranes. The membranes were incubated with rabbit anti-RORγt (Santa Cruz biotechnology, Santa Cruz, CA, USA), rat anti-IL-17A (Cell Signaling, Danvers, MA, USA) or goat anti-IL-17F (R&D Systems, Minneapolis, MN) primary antibody respectively overnight. The membranes were washed three times with TBST, followed by the incubation with the appropriate HRP-conjugated secondary antibody for 1 hour at the room temperature. The specific bands were identified with an Enhanced Chemiluminescence Detection Kit (Amersham Biosciences, Piscataway, NJ, USA). This test was repeated for at least three times.

ELISA
-----

The cells were treated as described in the "Flow cytometry" section. Six hours before the end of the treatment, the cells were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA) plus 1 μg/ml of ionomycin (Alexis, Lausen, Switzerland) for the below experiments. Supernatants were harvested from the above treated cells. To detect IL-17A and IL-17F in the cell culture supernatants, we used the mouse IL-17A ELISA Kit (DAKEWE, Shenzhen, China) or IL-17F ELISA kit (BioLegend, San Diego, CA) according to the manufacturer\'s instructions. Absorbance value was measured at 450 nm on a 680 type microplate reader (BIO-RAD, Berkeley, CA, USA.)

Immunofluorescence staining
---------------------------

The isolated CD4^+^ T cells were seeded in a 24-well plate at the density of 1.5 × 10^6^ cells/well and treated as described in the "Flow cytometry" section. The *In situ* expressions of RORγt, IL-17A and IL-17F in the treated CD4^+^ T cells were examined via immunofluorescence staining. The treated cells were fixed in cold methanol at 4°C for 10 min. Then, the cells were washed with PBS and blocked with 5% BSA in PBS for 30 min. The blocked cells were incubated with rabbit anti-RORγt (Santa Cruz biotechnology, Santa Cruz, CA, USA), rat anti-IL-17A (Cell Signaling, Danvers, MA, USA) and goat anti-IL-17F (R&D Systems, Minneapolis, MN) antibodies for 3 h at 4°C. Subsequently, the cells were incubated with a donkey anti-goat IgG-PE antibody (Santa Cruz biotechnology, Santa Cruz, CA, USA), a Alexa Fluor 488-conjugated anti-rat IgG antibody, a Alexa Fluor 488-conjugated anti-rabbit IgG antibody or a Alexa Fluor 647-conjugated anti-rabbit IgG antibody (Cell Signaling Technology, Inc.) for 1 h at 37°C. In addition, 6-diamidino-2-phenylindole (DAPI) or propidium iodide (PI) staining was performed for 5 min at the same temperature. The cells were detected using the Leica DMRA2 fluorescence microscope with FW4000 software (Leica, Germany). Positive cells or negative cells under 10 fields of view selected randomly for each group were counted for average percentages.

Statistical analysis
--------------------

Student\'s t-test was performed for the paired data comparison and one way ANOVA was followed for comparing the sets of more than two groups. P value \<0.05 was considered statistically significant.
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![The inhibition of CD4^+^ T cells towards Th17 cell differentiation by Jagged-1 signaling.\
The isolated CD4^+^ T cells were treated by Jagged-1 and quantitatively analyzed by the flow cytometry, 72 h after the treatment. (A) The levels of intracellular IL-17 in the treated CD4^+^ T cells. (B) Intracellular IL-17 and IFN-γ production in the treated CD4^+^ T cells. (C) Percentage of CD4^+^IL-17^+^ T cells. (D) Proportion of IL-17^+^ cells in the lower right quadrant in the FACS plots. Three independent experiments were repeated. \*\**p* \< 0.01, *vs.* the corresponding control.](srep08234-f1){#f1}

![Differential expressions of the genes relevant to the Th17 cell differentiation by Jagged-1 signaling.\
(A) The heat map provides a graphical representation of expression fold between the Jagged-1-treated CD4^+^ T cells (Jagged-1 group) and the untreated CD4^+^ T cells (control group). Red indicates the upregulated genes and green, the downregulated genes. (B) The both groups are overlaid onto the qPCR Array plate layout with genes\' name and their location. (C) The relative expressional levels for each gene in the Jagged-1 group and the control group are plotted against each other in the scatter plot. Red shows the upregulated genes and green, the downregulated genes. (D) Up/downregulated genes in CD4^+^ T cells from the Jagged-1 group are compared with the control group. Fold-change values greater than two hint the positive regulation, and fold-change values less than two, the negative regulation. Two independent experiments were repeated.](srep08234-f2){#f2}

![The decreased expressions of *Il17a*, *Il17f*, *Il12rb1* and *Il23a* genes in the Jagged-1-treated CD4^+^ T cells.\
(A--D) The expressions of *Il17a*, *Il17f*, *Il12rb1* and *Il23a* mRNA were evaluated by RT-PCR, and the PCR products were separated by electrophoresis on the 1.5% agarose gel. (E--H) the relative quantification of *Il17a*, *Il17f*, *Il12rb1* and *Il23a* mRNA expressions was performed using the 2^−ΔΔCt^ method by qPCR. The results are representative of the three independent experiments. \**p* \< 0.05, \*\**p* \< 0.01 *vs.* the corresponding control.](srep08234-f3){#f3}

![The downregulation of IL-17A, IL-17F and the RORγt expressions in the Jagged-1-treated CD4^+^ T cells.\
The isolated CD4^+^ T cells were treated with Jagged-1 for 72 h. (A--C) The relative quantification of *Il-17a*, *Il-17f* and *Rorγt* mRNA expressions was detected using 2^−ΔΔCt^ method by qPCR. (D--F) The levels of IL-17A, IL-17F and RORγt proteins were determined by Western Blot. (G and H) The levels of IL-17A and IL-17F secreted by the treated CD4^+^ T cells were measured by ELISA. The results are representative of the three independent experiments. \**p* \< 0.05, \*\**p* \< 0.01.](srep08234-f4){#f4}

![The *in situ* localization and distribution of IL-17A and IL-17F in the CD4^+^ T cells treated with Jagged-1.\
The isolated CD4^+^ T cells were treated with Jagged-1 for 72 h. The cells were fixed, permeablized and stained with monoclonal antibodies specific for IL-17A (green) and IL-17F (red). The nuclei were stained with DAPI (blue). All the cells were observed at magnification ×200. Three independent experiments were repeated. \**p* \< 0.05, *vs.* the corresponding control.](srep08234-f5){#f5}

![The *in situ* expressional relationship of both IL-17A and IL-17F to RORγt in the CD4^+^ T cells treated with Jagged-1.\
The isolated CD4^+^ T cells were treated with Jagged-1 for 72 h. The cells were fixed, permeablized and stained with monoclonal antibodies specific for IL-17A (green), IL-17F (red) and RORγt (blue). All the cells were observed at magnification ×200. Three independent experiments were repeated. \**p* \< 0.05, *vs.* the corresponding control.](srep08234-f6){#f6}

###### 84 genes assessed by qPCR array

  Symbol                                        Name                                      Symbol                                      Name
  --------- ---------------------------------------------------------------------------- --------- --------------------------------------------------------------------------
  Cacybp                             Calcyclin binding protein                             Ccl1                          Chemokine (C-C motif) ligand 1
  Ccl2                             Chemokine (C-C motif) ligand 2                          Ccl20                        Chemokine (C-C motif) ligand 20
  Ccl22                           Chemokine (C-C motif) ligand 22                          Ccl7                          Chemokine (C-C motif) ligand 7
  Cd2                                       CD2 antigen                                    Cd247                                 CD247 antigen
  Cd28                                      CD28 antigen                                   Cd34                                   CD34 antigen
  Cd3d                             CD3 antigen, delta polypeptide                          Cd3e                         CD3 antigen, epsilon polypeptide
  Cd3g                             CD3 antigen, gamma polypeptide                           Cd4                                   CD4 antigen
  Cd40lg                                    CD40 ligand                                    Cd8a                             CD8 antigen, alpha chain
  Cebpb                     CCAAT/enhancer binding protein (C/EBP), beta                  Clec7a                    C-type lectin domain family 7, member a
  Csf2                  Colony stimulating factor 2 (granulocyte-macrophage)               Csf3                    Colony stimulating factor 3 (granulocyte)
  Cx3cl1                         Chemokine (C-X3-C motif) ligand 1                         Cxcl1                        Chemokine (C-X-C motif) ligand 1
  Cxcl12                         Chemokine (C-X-C motif) ligand 12                         Cxcl2                        Chemokine (C-X-C motif) ligand 2
  Cxcl5                           Chemokine (C-X-C motif) ligand 5                         Il25                                  Interleukin 25
  S1pr1                          Sphingosine-1-phosphate receptor 1                        Foxp3                                Forkhead box P3
  Gata3                                GATA binding protein 3                              Icam1                       Intercellular adhesion molecule 1
  Icos                             Inducible T-cell co-stimulator                          Ifng                                 Interferon gamma
  Il10                                     Interleukin 10                                  Il12b                                Interleukin 12B
  Il12rb1                         Interleukin 12 receptor, beta 1                         Il12rb2                       Interleukin 12 receptor, beta 2
  Il13                                     Interleukin 13                                  Il15                                  Interleukin 15
  Il17a                                   Interleukin 17A                                  Il17c                                Interleukin 17C
  Il17d                                   Interleukin 17D                                  Il17f                                Interleukin 17F
  Il17rb                             Interleukin 17 receptor B                            Il17rc                           Interleukin 17 receptor C
  Il17rd                             Interleukin 17 receptor D                            Il17re                           Interleukin 17 receptor E
  Il18                                     Interleukin 18                                  Il1b                                Interleukin 1 beta
  Il2                                      Interleukin 2                                   Il21                                  Interleukin 21
  Il22                                     Interleukin 22                                  Il23a                       Interleukin 23, alpha subunit p19
  Il23r                               Interleukin 23 receptor                              Il27                                  Interleukin 27
  Il3                                      Interleukin 3                                    Il4                                  Interleukin 4
  Il5                                      Interleukin 5                                    Il6                                  Interleukin 6
  Il6ra                            Interleukin 6 receptor, alpha                           Il7r                              Interleukin 7 receptor
  Isg20                            Interferon-stimulated protein                           Jak1                                  Janus kinase 1
  Jak2                                     Janus kinase 2                                  Mmp13                           Matrix metallopeptidase 13
  Mmp3                               Matrix metallopeptidase 3                             Mmp9                            Matrix metallopeptidase 9
  Myd88                   Myeloid differentiation primary response gene 88                Nfatc2    Nuclear factor of activated T-cells, cytoplasmic,calcineurin-dependent 2
  Nfkb1      Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105    Rorc                        RAR-related orphan receptor gamma
  Socs1                          Suppressor of cytokine signaling 1                        Socs3                       Suppressor of cytokine signaling 3
  Stat3                  Signal transducer and activator of transcription 3                Stat4               Signal transducer and activator of transcription4
  Stat5a                Signal transducer and activator of transcription 5a                Stat6               Signal transducer and activator of transcription 6
  Sykb                                 Spleen tyrosine kinase                              Tbx21                                    T-box 21
  Tgfb1                          Transforming growth factor, beta 1                        Tirap      Toll-interleukin 1 receptor (TIR) domain-containing adaptor protein
  Tlr4                                  Toll-like receptor 4                                Tnf                              Tumor necrosis factor
  Traf6                           Tnf receptor-associated factor 6                          Yy1                             YY1 transcription factor
